Alexion Europe SAS

Company snapshot

Alexion, AstraZeneca Rare Disease, ist der Unternehmensbereich von AstraZeneca, der sich auf seltene Krankheiten konzentriert und durch die Übernahme von Alexion Pharmaceuticals, Inc. im Jahr 2021 entstand. Alexion ist seit 30 Jahren führend auf dem Gebiet der seltenen Erkrankungen und konzentriert sich darauf, betroffene Patient:innen und Familien, durch die Entdeckung, Entwicklung und Vermarktun

• 33 active pipeline program(s) linked via ClinicalTrials.gov.
• 33 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Alexion Europe SAS. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Alexion Europe SAS.

1. Jun 8, 2026 Clinical update

   ALXN1210-IgAN-325 — Phase 3

2. Jun 8, 2026 Clinical update

   AZP-3601-CLI-002 — Phase 3

3. Jun 8, 2026 Clinical update

   ALXN2220-ATTRCM-301 — Phase 3

4. Jun 8, 2026 Clinical update

   ALXN1850-HPP-303 — Phase 3

5. Jun 8, 2026 Clinical update

   ALXN1210-TMA-313 — Phase 3

View all clinical trial activity →

• What is Alexion Europe SAS?

  Alexion Pharma Germany is a pharma organization headquartered in EU. Primary therapeutic focus areas include Hypophosphatasia, Paroxysmal Nocturnal Hemoglobinuria, Lupus Nephritis (LN) Immunoglobulin A Nephropathy (IgAN), Acromegaly, BAG3 Mutation Associated Dilated Cardiomyopath

• Is Alexion Europe SAS publicly traded?

  Alexion Europe SAS appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Alexion Europe SAS develop or market?

  We link 40 drug profile(s) where Alexion Europe SAS is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/alexion-europe-sas#company-drugs.

• What are the latest developments for Alexion Europe SAS?

  In the last 12 months our linked public records show 33 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Alexion Europe SAS focus on?

  Alexion Europe SAS focuses on Hypophosphatasia, Paroxysmal Nocturnal Hemoglobinuria, Lupus Nephritis (LN) Immunoglobulin A Nephropathy (IgAN) based on our analysis of their pipeline programs and drug development activities.